Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology
April 19, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and development industry. AGOURA HILLS, Calif., April 19, 2023 ...
ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
April 17, 2023 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...
Oncotelic Announces Release of Pet2DAO Tokens (PDAO)
April 03, 2023 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Oncotelic Announces Pet2DAO Website is Live
March 20, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
PDAO is to Revolutionize Decentralized Autonomous Organization AGOURA HILLS, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or...
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
March 13, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC)...
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
February 06, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
January 25, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of...
Oncotelic Announces the launch of PDAO token
January 17, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
Oncotelic Issues Year End Message to Shareholders
December 28, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023- OT-101 commercialization effort expanding on multiple fronts - Manufacturing...
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
December 19, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...